Michela C.
- Country
- Italy
- Department
- Unita Operativa Complessa Malattie Muscolari e Neurodegenerative
Research Overview
- A Phase 3, Open-label, Single-arm, Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy, Safety, and Immunogenicity of Ravulizumab Administered Intravenously in Pediatric Participants (6 to < 18 years of age) with Generalized Myasthenia Gravis (gMG)
- Phase 2 Study of the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Inebilizumab in Pediatric Patients with Generalized Myasthenia Gravis
Data & Insights
Has run more than one trial at 0 of 14 partner sites.
Specializations
Neuromuscular Research
This investigator focuses on the clinical study of Generalized Myasthenia Gravis (gMG), a complex autoimmune neuromuscular disorder that affects pediatric populations.
- Pediatric Neurology
- Autoimmune Disorders
- Neuromuscular Junction Diseases
Specialized interest in evaluating novel therapeutic approaches for young patients aged 6 to 18 years with gMG.
Treatment Assessment
The investigator's work centers on examining pharmacokinetics and pharmacodynamics in pediatric populations with neuromuscular conditions.
- Drug Safety Evaluation
- Therapeutic Monitoring
- Immunogenicity Assessment
Expertise in analyzing treatment responses and safety profiles in young patients with autoimmune disorders.
Pediatric Medicine
Clinical expertise in pediatric therapeutic development with a focus on rare neuromuscular conditions.
- Rare Disease Treatment
- Pediatric Drug Development
- Clinical Safety Monitoring
Dedicated to advancing treatment options for pediatric patients with challenging autoimmune conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.